CARB-X funds ArrePath to advance novel antibiotic to treat multidrug-resistant infections
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award biotechnology company ArrePath US$3.7 million to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales.